The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback